Concepts (94)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteomyelitis | 3 | 2019 | 209 | 0.320 |
Why?
|
| Diabetic Foot | 3 | 2019 | 169 | 0.250 |
Why?
|
| Cytomegalovirus Infections | 3 | 2012 | 221 | 0.220 |
Why?
|
| Endocarditis, Bacterial | 2 | 2018 | 127 | 0.210 |
Why?
|
| Colistin | 2 | 2016 | 30 | 0.210 |
Why?
|
| Ganciclovir | 2 | 2012 | 101 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 2577 | 0.150 |
Why?
|
| Treatment Failure | 2 | 2019 | 347 | 0.150 |
Why?
|
| Splenic Diseases | 1 | 2018 | 28 | 0.140 |
Why?
|
| Staphylococcus epidermidis | 1 | 2018 | 39 | 0.140 |
Why?
|
| Antiviral Agents | 3 | 2012 | 800 | 0.130 |
Why?
|
| Abscess | 1 | 2018 | 137 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 147 | 0.130 |
Why?
|
| Bone and Bones | 1 | 2019 | 306 | 0.120 |
Why?
|
| Organ Transplantation | 2 | 2016 | 170 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 563 | 0.110 |
Why?
|
| Enterococcus | 2 | 2019 | 30 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2016 | 149 | 0.110 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 87 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2016 | 99 | 0.110 |
Why?
|
| Bacteria | 1 | 2019 | 524 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2016 | 231 | 0.100 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2016 | 158 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2016 | 237 | 0.100 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 264 | 0.100 |
Why?
|
| Liver Transplantation | 2 | 2012 | 1129 | 0.100 |
Why?
|
| Pediococcus | 1 | 2012 | 1 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2016 | 558 | 0.090 |
Why?
|
| Daptomycin | 1 | 2012 | 17 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 539 | 0.090 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2012 | 33 | 0.090 |
Why?
|
| Ribavirin | 1 | 2012 | 85 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 72 | 0.090 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2012 | 153 | 0.090 |
Why?
|
| Transplantation | 1 | 2010 | 25 | 0.080 |
Why?
|
| Chemoprevention | 1 | 2010 | 49 | 0.080 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2011 | 91 | 0.080 |
Why?
|
| Lung Abscess | 1 | 2009 | 15 | 0.080 |
Why?
|
| Empyema | 1 | 2009 | 23 | 0.080 |
Why?
|
| Cytomegalovirus | 1 | 2011 | 258 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 79 | 0.070 |
Why?
|
| HIV Seropositivity | 1 | 2009 | 125 | 0.070 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 395 | 0.070 |
Why?
|
| Bacteremia | 1 | 2012 | 430 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2018 | 12840 | 0.050 |
Why?
|
| Middle Aged | 7 | 2018 | 28325 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2012 | 3113 | 0.040 |
Why?
|
| Humans | 13 | 2019 | 130123 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2018 | 23 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 46 | 0.030 |
Why?
|
| Adult | 6 | 2016 | 31032 | 0.030 |
Why?
|
| Male | 7 | 2018 | 64386 | 0.030 |
Why?
|
| Leg | 1 | 2016 | 119 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 1237 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 478 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 170 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1166 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 1476 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 424 | 0.030 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 265 | 0.030 |
Why?
|
| Aged | 3 | 2016 | 20829 | 0.030 |
Why?
|
| Leukopenia | 1 | 2012 | 44 | 0.020 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 324 | 0.020 |
Why?
|
| Aerosols | 1 | 2012 | 57 | 0.020 |
Why?
|
| DNA, Ribosomal Spacer | 1 | 2012 | 7 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1606 | 0.020 |
Why?
|
| Palivizumab | 1 | 2012 | 48 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2018 | 947 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 724 | 0.020 |
Why?
|
| Pancreas Transplantation | 1 | 2011 | 30 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2057 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 932 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2018 | 1212 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 10950 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 479 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 708 | 0.020 |
Why?
|
| Vancomycin Resistance | 1 | 2009 | 22 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2012 | 1208 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5161 | 0.020 |
Why?
|
| Coinfection | 1 | 2011 | 186 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 15006 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 565 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 3463 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2012 | 1692 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 551 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 6765 | 0.010 |
Why?
|
| Female | 3 | 2016 | 70274 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2012 | 3679 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 6177 | 0.010 |
Why?
|
| Young Adult | 1 | 2016 | 9986 | 0.010 |
Why?
|
| Infant | 1 | 2016 | 13275 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2016 | 17547 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 20800 | 0.010 |
Why?
|
| Child | 1 | 2016 | 26175 | 0.010 |
Why?
|